


FDA surrogate framework: glucose trajectory is a replicated risk marker,
not a fully-qualified surrogate endpoint (PTE $\approx$ 0.02)



C1 passes in both databases (phenotype is treatment-responsive); C2/C3 fail at population level → candidate surrogate requiring prospective RCT confirmation.